ERBB2 and breast carcinoma: Targeted approaches have recently been developed in the cancer field [39,40] whereby conjugating sialidase (the enzyme that removes Sialic acid from glycans) to trastuzumab (Herceptin; an antibody against HER2+ breast cancer cells) selectively desialylated HER2+ breast cancer cells.